We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Myopathy Diagnosis Improved by New Gene Mutation

By LabMedica International staff writers
Posted on 08 Jan 2014
A new gene mutation has been discovered which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children.

Mitochondrial myopathy causes muscle weakness, movement problems, and learning difficulties, and for the first time, mutations in a particular gene have been linked to myopathy and this discovery gives a better understanding of the genetic causes of the condition.

An international team of scientists led by those at the St. More...
James's University Hospital (Leeds, UK) studied a cohort of subjects who presented in childhood with a distinctive clinical phenotype comprising early-onset proximal muscle weakness with a static course and moderately to grossly elevated serum creatine kinase levels accompanied by learning difficulties. Muscle biopsies were available for 6 of 15 affected individuals. All showed myopathic features, with diffuse variation in fiber size, increased frequency of internal and central nuclei and clusters of regenerating fibers, without pronounced fibrosis or fatty infiltration.

The investigator identified two mutations in the mitochondrial calcium uptake 1 (MICU1) gene using a technique called exome sequencing which is an alternative to whole genome sequencing. They performed homozygosity analysis using a Genome-Wide Human single nucleotide polymorphism (SNP) Array (Affymetrix; Santa Clara, CA, USA). Whole-exome sequencing of one subject identified only one potentially pathogenic variant in the homozygous region, a splice acceptor site mutation, in MICU1. The team found that mutations in the MICU1 gene caused less protein to be produced which led to an increase in calcium in the mitochondria. This resulted in damage to the mitochondria and changes in calcium levels in the rest of the cell.

Eamonn Sheridan, MB ChB, one of the lead authors of the study said, “The results of this study will enable clinicians to give individuals a more precise diagnosis, and information on how the condition might progress, as well as helping families to make better-informed decisions.” Although it is not known precisely how changes in the cell lead to myopathy, the findings will help provide useful information about the causes of myopathy and how to develop future therapies. The study was published on December 15, 2013, in the journal Nature Genetics.

Related Links:

St. James's University Hospital 
Affymetrix 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.